Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.

Heinzerling, Lucie; Eigentler, Thomas K; Fluck, Michael; Hassel, Jessica C; Heller-Schenck, Daniela; Leipe, Jan; Pauschinger, Matthias; Vogel, Arndt; Zimmer, Lisa; Gutzmer, Ralf

Heinzerling, Lucie; Eigentler, Thomas K; Fluck, Michael; Hassel, Jessica C; Heller-Schenck, Daniela; Leipe, Jan; Pauschinger, Matthias; Vogel, Arndt; Zimmer, Lisa; Gutzmer, Ralf.

Afiliação

Heinzerling L; Department of Dermatology, University of Erlangen, Erlangen, Germany.
Eigentler TK; Department of Dermatology, Center for Dermatooncology, University Medical Center Tübingen, Tübingen, Germany.
Fluck M; Department of Internal Medicine, Fachklinik Hornheide, Münster, Germany.
Hassel JC; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
Heller-Schenck D; MVZ Augenärzte am Kröpcke, Hannover, Germany.
Leipe J; Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany.
Pauschinger M; Department of Cardiology, Klinikum Nürnberg Süd, Paracelsus Medical University Nürnberg, Nuremberg, Germany.
Vogel A; Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Zimmer L; Department of Dermatology, University Hospital, University Essen-Duisburg, Essen, Germany.
Gutzmer R; German Cancer Consortium (DKTK), Heidelberg, Germany.

ESMO Open ; 4(3): e000491, 2019.

Article em En | MEDLINE | ID: mdl-31231568

Palavras-chave

BRAF; MEK; adverse events; melanoma; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: ESMO Open Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google